PARP抑制剂在遗传性乳腺癌、卵巢癌和其他癌症中的作用:综述

4区生物学 Q2 Biochemistry, Genetics and Molecular Biology

Advances in Genetics Pub Date : 2021-01-01 Epub Date: 2021-10-23 DOI:10.1016/bs.adgen.2021.08.002

Prashant Mehta, Sneha J Bothra

{"title":"PARP抑制剂在遗传性乳腺癌、卵巢癌和其他癌症中的作用:综述","authors":"Prashant Mehta, Sneha J Bothra","doi":"10.1016/bs.adgen.2021.08.002","DOIUrl":null,"url":null,"abstract":"There has been a paradigm shift in the management of cancer, with the immense progress in cancer genomics. More and more targeted therapies are becoming available by the day and personalized medicine is becoming popular with specific drugs being designed for selected subgroups of patients. One such new class of targeted drugs in the armamentarium is Poly ADP Ribose Polymerase (PARP) inhibitors (PARPi), which inhibit the enzyme PARP, thus interfering with DNA repair. This strategy utilizes a pre-existing genomic lesion in tumors with homologous recombination repair defects (including BRCA mutations), weakening tumor cells further by blocking the alternate pathway of DNA repair. In this review, we discuss in detail, the evolution, genetics, mechanism of action, mechanism of resistance, indications of use of PARP inhibitors, as well as combination with other agents and future directions.","PeriodicalId":50949,"journal":{"name":"Advances in Genetics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.\",\"authors\":\"Prashant Mehta, Sneha J Bothra\",\"doi\":\"10.1016/bs.adgen.2021.08.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There has been a paradigm shift in the management of cancer, with the immense progress in cancer genomics. More and more targeted therapies are becoming available by the day and personalized medicine is becoming popular with specific drugs being designed for selected subgroups of patients. One such new class of targeted drugs in the armamentarium is Poly ADP Ribose Polymerase (PARP) inhibitors (PARPi), which inhibit the enzyme PARP, thus interfering with DNA repair. This strategy utilizes a pre-existing genomic lesion in tumors with homologous recombination repair defects (including BRCA mutations), weakening tumor cells further by blocking the alternate pathway of DNA repair. In this review, we discuss in detail, the evolution, genetics, mechanism of action, mechanism of resistance, indications of use of PARP inhibitors, as well as combination with other agents and future directions.\",\"PeriodicalId\":50949,\"journal\":{\"name\":\"Advances in Genetics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Genetics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.adgen.2021.08.002\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/10/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.adgen.2021.08.002","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 3

摘要

随着癌症基因组学的巨大进步，癌症管理的模式发生了转变。如今，越来越多的靶向治疗变得可行，个性化医疗也变得流行起来，为选定的亚组患者设计特定的药物。其中一类新的靶向药物是聚ADP核糖聚合酶(PARP)抑制剂(PARPi)，它抑制PARP酶，从而干扰DNA修复。该策略利用同源重组修复缺陷(包括BRCA突变)肿瘤中预先存在的基因组损伤，通过阻断DNA修复的替代途径进一步削弱肿瘤细胞。本文就PARP抑制剂的进化、遗传学、作用机制、耐药机制、使用适应症、与其他药物的联用及未来发展方向等方面进行了综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.

There has been a paradigm shift in the management of cancer, with the immense progress in cancer genomics. More and more targeted therapies are becoming available by the day and personalized medicine is becoming popular with specific drugs being designed for selected subgroups of patients. One such new class of targeted drugs in the armamentarium is Poly ADP Ribose Polymerase (PARP) inhibitors (PARPi), which inhibit the enzyme PARP, thus interfering with DNA repair. This strategy utilizes a pre-existing genomic lesion in tumors with homologous recombination repair defects (including BRCA mutations), weakening tumor cells further by blocking the alternate pathway of DNA repair. In this review, we discuss in detail, the evolution, genetics, mechanism of action, mechanism of resistance, indications of use of PARP inhibitors, as well as combination with other agents and future directions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Genetics 生物-遗传学

CiteScore

5.70

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Advances in Genetics presents an eclectic mix of articles of use to all human and molecular geneticists. They are written and edited by recognized leaders in the field and make this an essential series of books for anyone in the genetics field.